Drugs / LY4268989
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07707375 | Jul → Oct 2026 expected | — | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06964776 | May 2025 → Feb 2026 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07415044 | Mar 2026 → Jun 2030 expected | ulcerative colitis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07186101 | Nov 2025 → May 2027 expected | ulcerative colitis | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4268989 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07186101 ↗ |
| Known as | MORF-057 | “A Study of LY4268989 (MORF-057) in Healthy Participants” NCT06964776 ↗ |
| Known as | MORF-57 | “The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989...” NCT06964776 ↗ |
| Route | Oral | “Administered orally” NCT06964776 ↗ |